Clinical Takeaway
In this phase 3 trial of 820 adults with chronic low back pain, the full-spectrum cannabis extract VER-01 was evaluated over a 12-week double-blind period followed by longer-term open-label phases. The trial design allows for robust assessment of both short- and long-term efficacy and safety compared to placebo. Results from this study contribute meaningful clinical evidence toward cannabis-based options for a condition where current treatments frequently fall short.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by providing rigorous evidence for cannabis-based therapy in chronic low back pain, a condition affecting over 500 million people globally where current pharmacologic options demonstrate inadequate efficacy and safety profiles. The large sample size (820 participants) and robust double-blind design strengthen the evidentiary foundation necessary for informed clinical decision-making and potential regulatory approval of full-spectrum cannabis extracts as an alternative to conventional analgesics and opioids. These findings could reshape pain management guidelines by offering clinicians a pharmacologically distinct option for patients who fail or cannot tolerate existing treatments.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
💊 This phase 3 trial of a full-spectrum cannabis extract for chronic low back pain represents meaningful progress in a therapeutic area where conventional pharmacotherapy remains suboptimal, though several factors warrant cautious interpretation of the findings. The 12-week double-blind phase with 820 participants provides reasonable statistical power, but the incomplete abstract limits assessment of primary efficacy endpoints, effect sizes, and whether benefits persist through the open-label extension—a critical distinction since placebo responses in pain trials are notoriously robust. Important confounders to consider include the heterogeneity of CLBP itself, variable cannabinoid profiles across batches of full-spectrum extracts, potential selection bias in open-label phases, and whether observed improvements reflect cannabinoid pharmacology or broader contextual factors common to pain management programs. Clinically, while this study may eventually support cannabis as an option for patients with CLBP who have failed or cannot tolerate conventional treatments, current evidence remains insufficient to recommend full-spectrum cannabis extract as first-line